AH BIO FUND IV, L.P. purchased 12.0% of their position (1.10M shares) of BRAVEHEART BIO, INC. on the open market
Open‑market purchase worth $19.80M — a moderate purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 8/11/2026ACC: 0001231919-26-000859
10% Owner
Since Aug 2026
-29.77M
Net shares
Net seller
$19.80M
Total acquired
1
Open market trades
1B · 0S
3
Total transactions
10.23M acquired · 40M disposed
Non-Derivative Transactions2
Common Stock
Indirect
Shares
+9.13M
Price / share
—
Trade value
—
% of position
New position
8/7/2026
0.00→9.13M
Common Stock
Indirect
Shares
+1.10M
Price / share
$18.00
Trade value
$19.80M
% of position
12.0%
8/7/2026
9.13M→10.23M
Total
Net shares
+10.23M
Net value
$19.80M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 8/7/2026 | C · Conversion | +9.13M | — | — | New position | 0.00 | 9.13M |
| Common Stock Indirect | 8/7/2026 | P · Purchase | +1.10M | $18.00 | $19.80M | 12.0% | 9.13M | 10.23M |
| Total | +10.23M | $19.80M | ||||||
Derivative Transactions1
Series A Preferred Stock
Indirect
Converts to
Common Stock
9.13M shares
Shares
−40M
Strike price
Held after
0.00
Exercisable
—
8/7/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Series A Preferred Stock Indirect | Common Stock9.13M shares | 8/7/2026 | C · Conversion | −40M | — | 0.00 |